Kiniksa (KNSA) | Stock Overview & Key Data
Kiniksa Performance Comparison
Stock Range
Today's Range
Low: $37.95
High: $38.83
on October 6, 2025
52 Week Range
Low: $17.82
High: $39.12
on January 13, 2025
on October 1, 2025
All-Time High: $39.12 on October 1, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$2.9B
EPS
0.05
P/E Ratio (TTM)
769.80
Forward P/E
69.98
P/B Ratio
5.76
PEG Ratio
-1.54
Div. Yield
N/A
ROE
1.03%
Beta
0.161
Debt to Equity
1.97
Financial Highlights
Profitability
Gross Margin
54.71%
Operating Margin
12.86%
Profit Margin
0.90%
Returns and Earnings
Return on Assets (TTM)
0.47%
Return on Equity (TTM)
1.03%
EBITDA
$6.0M
Net Income (TTM)
$4.8M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$7.30
Quarterly Revenue Growth (YoY)
44.30%
Quarterly Earnings Growth (YoY)
44.34%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Kiniksa KNSA | 2.85B Mid-cap | -1.24% | 4.70% | 36.99% | 88.81% | 92.03% | 44.16% | 182.17% | 107.98% |
| Zoetis ZTS | 65.09B Large-cap | 2.03% | -3.94% | -8.02% | -8.26% | -9.96% | -22.95% | -0.64% | -11.49% |
| Haleon Plc - ADR HLN | 41.44B Large-cap | -0.57% | -9.75% | -13.40% | -5.18% | -6.89% | -12.54% | 45.53% | 18.62% |
| Regencell Bioscience RGC | 8.46B Mid-cap | 5.25% | 28.44% | -6.40% | 2,169.74% | 13,169.23% | 10,681.25% | 2,169.74% | 6,060.71% |
| Alkermes plc ALKS | 5.26B Mid-cap | 6.71% | 8.93% | 6.02% | 5.09% | 7.79% | 7.19% | 37.00% | 80.91% |
| Prestige Consumer PBH | 3.79B Mid-cap | 2.00% | -3.95% | -19.93% | -22.43% | -18.70% | -9.18% | 24.81% | 74.13% |
Ownership & Short Interest
Insider Ownership
3.72%
Institutional Ownership
93.07%
Shares Short
2M
Short Ratio
5.56
Short % of Shares Outstanding
6.07%
Average 10-Day Volume
459K
Average 90-Day Volume
427K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is KNSA's 52-week high and low?
- In the last 52 weeks, Kiniksa reached a high of $39.12 (on October 1, 2025) and a low of $17.82 (on January 13, 2025).
- What is the market cap and P/E ratio for KNSA?
- Curious about Kiniksa's size and valuation? Its market capitalization stands at 2.85B. When it comes to valuation, the P/E ratio (trailing twelve months) is 769.80, and the forward P/E (looking ahead) is 69.98.
- Does KNSA pay dividends? If so, what's the yield?
- As for dividends, Kiniksa isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Kiniksa's main competitors or similar companies to consider before investing?
When looking at Kiniksa, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS65.09B Healthcare Drug Manufacturers - Specialty & Generic -22.95% -0.64% Haleon Plc - ADR
HLN41.44B Healthcare Drug Manufacturers - Specialty & Generic -12.54% 45.53% Regencell Bioscience
RGC8.46B Healthcare Drug Manufacturers - Specialty & Generic 10,681.25% 2,169.74% Alkermes plc
ALKS5.26B Healthcare Drug Manufacturers - Specialty & Generic 7.19% 37.00% Prestige Consumer
PBH3.79B Healthcare Drug Manufacturers - Specialty & Generic -9.18% 24.81% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Kiniksa Pharmaceuticals, Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Kiniksa's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 1.03%, the Debt to Equity ratio from the most recent quarter is 1.97, and its Gross Profit Margin stands at 54.71%.
- What is the recent revenue and earnings growth for KNSA?
- Looking at Kiniksa's growth, its revenue over the trailing twelve months (TTM) was $529M. Compared to the same quarter last year (YoY), quarterly revenue grew by 44.30%, and quarterly earnings saw a YoY growth of 44.34%.
- How much of KNSA stock is held by insiders and institutions?
- Wondering who owns Kiniksa stock? Company insiders (like executives and directors) hold about 3.72% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 93.07%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.